NeOnc Technologies Holdings, Inc. (NTHI) AI Stock Analysis

• Market Cap: $223.89M
• Dividend Yield: N/A
• Average Volume (3M): 103.40K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.80
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 23,970,790
• 10 Day Avg. Volume: 39,098
• 30 Day Avg. Volume: 103,402
• PEG Ratio: 0.71
• Price to Book (P/B): -32.79
• Price to Sales (P/S): 2174.97
• P/FCF Ratio: -42.84
• Enterprise Value/Market Cap: 0.30
• Enterprise Value/Revenue: 1.14K
• Enterprise Value/Gross Profit: 1.14K
• Enterprise Value/Ebitda: -1.28
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: $10.00 ▲(12.61% Upside)

The score is held back primarily by weak financial fundamentals (continued large losses, negative equity, and heavier cash burn). Offsetting this, technicals are moderately positive (price above key moving averages with positive MACD), and recent corporate updates are constructive (clinical data and partnership/financing announcements), while valuation remains constrained by ongoing unprofitability.

Positive Factors

Promising clinical efficacy of NEO100

Robust radiographic responses and strong six‑month progression‑free survival in recurrent high‑grade glioma signal NEO100 may offer meaningful survival benefit where options are limited. Durable efficacy with clean safety improves commercial and regulatory prospects and supports long‑term adoption.

$50M strategic partnership with Quazar

A large strategic partnership plus NIH funding materially strengthens funding runway and provides resources to scale clinical programs and infrastructure. This reduces execution risk, accelerates trials and regional expansion, and bolsters long‑term development and commercialization capacity.

Material reduction in total debt

Sharp debt reduction meaningfully lowers leverage and interest obligations, improving financial flexibility. With less debt pressure, management can prioritize clinical development and partnerships rather than debt servicing, supporting sustainable operations over the medium term.

Negative Factors

Heavy and worsening cash burn

Persistent and increasing negative operating cash flow indicates reliance on external financing to sustain trials and operations. This structural cash burn elevates dilution risk, could constrain trial timelines if funding gaps arise, and pressures management to secure recurring capital.

Negative stockholders' equity

Negative equity reflects accumulated losses and an impaired capital base, which can limit access to favorable financing, reduce counterparty confidence, and complicate strategic transactions. Over the medium term, it signals the need to rebuild equity via funding or sustained profits.

Large recurring net losses

Significant recurring net losses driven by development and operating costs versus small, improving revenue mean profitability is distant. Until commercial revenues scale, losses will persist, pressuring margins and necessitating continued capital raises or partnerships to fund R&D and operations.

NeOnc Technologies Holdings, Inc. Business Overview & Revenue Model

Company Description

Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.

How the Company Makes Money

NeOnc Technologies Holdings, Inc. Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	59.99K	83.00K	70.46K	20.00K	0.00
Gross Profit	59.99K	83.00K	70.46K	20.00K	0.00
EBITDA	-53.23M	-9.10M	-12.20M	-2.85M	-3.26M
Net Income	-54.55M	-11.90M	-14.92M	-3.05M	-3.38M
Balance Sheet
Total Assets	4.08M	3.42M	1.27M	728.68K	32.49K
Cash, Cash Equivalents and Short-Term Investments	1.51M	64.89K	31.86K	633.30K	25.03K
Total Debt	378.74K	24.72K	6.61M	50.00K	1.15M
Total Liabilities	15.90M	8.92M	15.25M	2.30M	2.65M
Stockholders Equity	-11.81M	-5.50M	-13.99M	-1.58M	-2.62M
Cash Flow
Free Cash Flow	-17.73M	-4.21M	-1.88M	-881.74K	-396.69K
Operating Cash Flow	-17.73M	-4.21M	-1.88M	-881.74K	-396.69K
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	17.91M	4.25M	1.28M	1.49M	250.00K

NeOnc Technologies Holdings, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NTHI	53 Neutral	$223.89M	-2.96	―	―	―	―
SNSE	52 Neutral	$15.11M	-0.54	-67.47%	―	―	9.63%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GTBP	47 Neutral	$7.02M	-0.22	-356.99%	―	―	54.62%
SLRX	44 Neutral	$5.23M	-0.02	-139.55%	―	―	68.08%
GOVX	44 Neutral	$4.95M	-0.06	-377.44%	―	8.52%	79.51%
CLDI	44 Neutral	$8.03M	-0.12	―	―	―	87.42%

NeOnc Technologies Holdings, Inc. Corporate Events

NeOnc Technologies Reports Promising Clinical Trial Results

On December 15, 2025, NeOnc Technologies Holdings, Inc. reported updated results from its clinical trials evaluating intranasal NEO100 for recurrent WHO Grade III/IV IDH1-mutant astrocytoma patients. Results showed significant advancements, as 24% of trial participants achieved radiographic remission, substantially outperforming typical rates of salvage therapies. Additionally, 44% of patients achieved progression-free survival at six months, and 36% demonstrated durable survival for at least 18 months. These findings point to NEO100’s potential as a transformative CNS-penetrant metabolic therapy with significant survival benefits in heavily pretreated populations, challenging historically palliative approaches. No toxicity concerns were observed, further backing its promise to improve treatment outcomes for CNS cancer patients.

NeOnc Technologies Announces Securities Purchase Agreement

On December 1, 2025, NeOnc Technologies Holdings, Inc. announced a Securities Purchase Agreement with investor Saad Naja for the sale of 111,732 shares of common stock at $8.95 per share, raising approximately $1 million to be used for working capital. Additionally, NeOnc revealed preclinical findings from a collaboration with the University of Southern California, showing that ultrasound enhances the effectiveness of NEO100 in treating brain tumors, potentially expanding its clinical and commercial opportunities.

NeOnc Technologies Secures $50M Partnership with Quazar

NeOnc Technologies Holdings, Inc. announced significant corporate and clinical developments for Q3 2025. The company reported progress in its NEO100 and NEO212 clinical trials, with NEO100 showing promising Phase 2a results for recurrent brain cancer. Additionally, NeOnc secured a $50 million partnership with Quazar Investment and received $2.5 million in NIH funding, enhancing its financial and strategic positioning. The appointment of key leadership figures and inclusion in the Russell Microcap Index further bolster its market visibility and institutional investor exposure. These developments indicate a strengthened foundation for NeOnc’s long-term growth and innovation in CNS oncology.

NeOnc Technologies Reports Promising Clinical Trial Results

On November 12, 2025, NeOnc Technologies Holdings, Inc. announced updated clinical results from its Phase 1/2a and compassionate care studies involving 24 patients with recurrent Grade III/IV IDH1-mutant astrocytoma treated with NEO100. The results showed significant radiographic response in 21% of patients and a 44% six-month progression-free survival rate, surpassing historical benchmarks. Additionally, 33% of patients demonstrated long-term survival of 18 months or more, with no significant toxicity reported. These findings suggest NEO100 could represent a paradigm shift in treating recurrent IDH1-mutant gliomas, potentially offering a new standard of care.

NeOnc Technologies Schedules Investor Call for Trial Updates

On November 7, 2025, NeOnc Technologies Holdings, Inc. announced an investor conference call scheduled for November 12, 2025, to present data updates from its ongoing Phase 1/2a NEO100-1 clinical trial and compassionate use program. The discussion will focus on MRI-based radiographic response data, progression-free survival, and overall survival trends for patients with recurrent high-grade malignant glioma, potentially impacting the company’s operations and industry positioning.

NeOnc Technologies Appoints Amir Heshmatpour as New CEO

On October 31, 2025, NeOnc Technologies Holdings, Inc. announced significant leadership changes with Dr. Thomas Chen resigning as CEO to focus on his roles as Chief Medical Officer and Chief Scientific Officer. Amir Heshmatpour was appointed as the new CEO, effective immediately, while continuing his roles as President and Executive Chairman. This leadership transition is part of NeOnc’s strategy to advance its clinical trials and capitalize on Heshmatpour’s expertise in corporate strategy and business development, aiming to drive the company’s next phase of growth and innovation in CNS cancer therapies.

NeOnc Technologies Appoints New Executive Chairman

On October 28, 2025, NeOnc Technologies Holdings, Inc. announced that His Highness Sheikh Nahyan bin Zayed Al Nahyan will assume the role of Executive Chairman of NuroMENA Holdings Ltd., its Middle East subsidiary. This strategic move is expected to significantly impact the company’s operations and position the UAE at the forefront of brain cancer treatment innovation, leveraging sovereign resources to address global health challenges.